EAM
UTHR icon

Exome Asset Management’s United Therapeutics UTHR Stock Holding History

Exome Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Sell
5,410
-1,643
-23% -$925K 1.81% 22
2026
Q1 		$4.18M Sell
7,053
-632
-8% -$315K 2.16% 15
2025
Q4 		$3.74M Buy
7,685
+1,040
+16% +$484K 1.79% 16
2025
Q3 		$2.79M Buy
+6,645
New +$2.23M 1.69% 23

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Exome Asset Management's UTHR Position: Q2 2026 in Review

Exome Asset Management reduced its United Therapeutics (UTHR) stake by 23% in Q2 2026, selling an estimated $925K and leaving 5,410 shares worth $2.93M. The position accounts for 1.81% of the portfolio, ranked #22.

Exome Asset Management first reported a position in UTHR in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.18M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Exome Asset Management held 5,410 shares of United Therapeutics worth $2.93M as of Q2 2026.
  • Exome Asset Management sold 1,643 United Therapeutics shares in Q2 2026, an estimated $925K.
  • United Therapeutics made up 1.81% of Exome Asset Management's portfolio in Q2 2026, its #22 holding.
  • Exome Asset Management first reported a position in United Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Exome Asset Management's United Therapeutics position peaked at $4.18M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.